CN101528733B - 作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮 - Google Patents

作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮 Download PDF

Info

Publication number
CN101528733B
CN101528733B CN2007800394514A CN200780039451A CN101528733B CN 101528733 B CN101528733 B CN 101528733B CN 2007800394514 A CN2007800394514 A CN 2007800394514A CN 200780039451 A CN200780039451 A CN 200780039451A CN 101528733 B CN101528733 B CN 101528733B
Authority
CN
China
Prior art keywords
compound
phenyl
trifluoromethyl
treatment
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800394514A
Other languages
English (en)
Chinese (zh)
Other versions
CN101528733A (zh
Inventor
J·M·肖斯
P·C·赫斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101528733A publication Critical patent/CN101528733A/zh
Application granted granted Critical
Publication of CN101528733B publication Critical patent/CN101528733B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800394514A 2006-10-23 2007-10-22 作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮 Expired - Fee Related CN101528733B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
US60/862,540 2006-10-23
PCT/US2007/082041 WO2008070305A2 (en) 2006-10-23 2007-10-22 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator

Publications (2)

Publication Number Publication Date
CN101528733A CN101528733A (zh) 2009-09-09
CN101528733B true CN101528733B (zh) 2013-10-16

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800394514A Expired - Fee Related CN101528733B (zh) 2006-10-23 2007-10-22 作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮
CN2007800394497A Expired - Fee Related CN101528732B (zh) 2006-10-23 2007-10-22 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800394497A Expired - Fee Related CN101528732B (zh) 2006-10-23 2007-10-22 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮

Country Status (23)

Country Link
US (2) US8168659B2 (cg-RX-API-DMAC10.html)
EP (2) EP2099784B1 (cg-RX-API-DMAC10.html)
JP (2) JP5331002B2 (cg-RX-API-DMAC10.html)
KR (2) KR101088229B1 (cg-RX-API-DMAC10.html)
CN (2) CN101528733B (cg-RX-API-DMAC10.html)
AR (1) AR063497A1 (cg-RX-API-DMAC10.html)
AT (1) ATE492543T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007329808B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0717347A2 (cg-RX-API-DMAC10.html)
CA (2) CA2667372C (cg-RX-API-DMAC10.html)
CL (1) CL2007003002A1 (cg-RX-API-DMAC10.html)
CY (1) CY1111140T1 (cg-RX-API-DMAC10.html)
DE (1) DE602007011495D1 (cg-RX-API-DMAC10.html)
DK (2) DK2099784T3 (cg-RX-API-DMAC10.html)
EA (2) EA015175B1 (cg-RX-API-DMAC10.html)
ES (2) ES2398388T3 (cg-RX-API-DMAC10.html)
MX (2) MX2009004053A (cg-RX-API-DMAC10.html)
PE (1) PE20080926A1 (cg-RX-API-DMAC10.html)
PL (2) PL2094684T3 (cg-RX-API-DMAC10.html)
PT (2) PT2099784E (cg-RX-API-DMAC10.html)
SI (2) SI2094684T1 (cg-RX-API-DMAC10.html)
TW (1) TW200825067A (cg-RX-API-DMAC10.html)
WO (2) WO2008070306A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
BRPI0910775A2 (pt) 2008-04-22 2015-09-29 Lilly Co Eli compostos 1,5-difenil pirrolidin-2-ona como ligantes cb-1
US8426448B2 (en) 2008-04-22 2013-04-23 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005080345A2 (en) * 2004-02-19 2005-09-01 Solvay Pharmaceuticals B.V. Imidazoline derivatives having cb1-antagonistic activity
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005080345A2 (en) * 2004-02-19 2005-09-01 Solvay Pharmaceuticals B.V. Imidazoline derivatives having cb1-antagonistic activity
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
EA015175B1 (ru) 2011-06-30
PL2099784T3 (pl) 2013-05-31
PE20080926A1 (es) 2008-07-19
ES2356025T3 (es) 2011-04-04
EA015745B1 (ru) 2011-10-31
SI2099784T1 (sl) 2013-02-28
CY1111140T1 (el) 2015-06-11
SI2094684T1 (sl) 2011-04-29
MX2009004054A (es) 2009-04-27
EP2094684B1 (en) 2010-12-22
JP5331002B2 (ja) 2013-10-30
EA200970405A1 (ru) 2009-12-30
CA2667372A1 (en) 2008-06-12
AU2007329808A1 (en) 2008-06-12
WO2008070306A3 (en) 2008-07-31
CN101528733A (zh) 2009-09-09
DK2094684T3 (da) 2011-03-14
CN101528732B (zh) 2013-04-03
KR101088236B1 (ko) 2011-11-30
BRPI0717347A2 (pt) 2014-01-14
JP5331001B2 (ja) 2013-10-30
CN101528732A (zh) 2009-09-09
US20090275618A1 (en) 2009-11-05
CA2667210C (en) 2013-09-24
ES2398388T3 (es) 2013-03-15
EP2099784B1 (en) 2012-12-12
KR20090071613A (ko) 2009-07-01
DK2099784T3 (da) 2013-01-14
JP2010507589A (ja) 2010-03-11
PL2094684T3 (pl) 2011-05-31
EP2094684A2 (en) 2009-09-02
MX2009004053A (es) 2009-04-27
WO2008070305A2 (en) 2008-06-12
ATE492543T1 (de) 2011-01-15
EA200970404A1 (ru) 2009-10-30
CA2667210A1 (en) 2008-06-12
US20100016375A1 (en) 2010-01-21
EP2099784A2 (en) 2009-09-16
DE602007011495D1 (de) 2011-02-03
KR101088229B1 (ko) 2011-11-30
PT2094684E (pt) 2011-01-28
AR063497A1 (es) 2009-01-28
AU2007329807A1 (en) 2008-06-12
WO2008070305A3 (en) 2008-08-28
PT2099784E (pt) 2013-01-04
AU2007329808B2 (en) 2013-11-07
CL2007003002A1 (es) 2008-06-06
JP2010507590A (ja) 2010-03-11
TW200825067A (en) 2008-06-16
WO2008070306A2 (en) 2008-06-12
US7998985B2 (en) 2011-08-16
US8168659B2 (en) 2012-05-01
CA2667372C (en) 2013-09-03
KR20090069316A (ko) 2009-06-30

Similar Documents

Publication Publication Date Title
EP2350020B1 (en) Spiro-imidazolone derivatives as glucagon receptor antagonists
EP2099784B1 (en) 1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-ones as cb1 receptor modulators
KR20140002709A (ko) Ｆａａｈ 저해제
PL213669B1 (pl) Pochodna 2-okso-1-pirolidyny, srodek farmaceutyczny i zastosowanie pochodnej 2-okso-1-pirolidyny
JP2010500372A (ja) オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CN106068265B (zh) 用于治疗代谢病症的二氢吡啶酮mgat2抑制剂
WO1999048492A1 (en) Amide derivatives and nociceptin antagonists
KR20150082617A (ko) 디히드로피라졸 gpr40 조절제
KR20150082616A (ko) 디히드로피라졸 gpr40 조절제
TW200811165A (en) N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
TW200810752A (en) Modulators of muscarinic receptors
JP2007513105A (ja) イミダゾール誘導体、その製法及び使用
CN106061968A (zh) 四唑酮‑取代的二氢吡啶酮mgat2抑制剂
US20070179172A1 (en) Positive modulators of nicotinic acetylcholine receptors
CN100436414C (zh) 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
CN101910126B (zh) 作为大麻素受体之配体的脯氨酸类似物
CN114901642B (zh) 一种稠环化合物及其应用
JP2012505834A (ja) ニコチン性アセチルコリン受容体リガンドおよびその使用
CN111566091A (zh) 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基衍生物
WO2023078392A1 (zh) 2-(芳基-2-基)吗啉及其氘代衍生物、制备方法和应用
AU2007329807B2 (en) 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulator
CN107459510A (zh) 异恶唑类化合物及其应用
HK40033115B (en) Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131016

Termination date: 20141022

EXPY Termination of patent right or utility model